Universal Biosensors 

A$0.14
5
+A$0.01+3.7% Friday 02:45

統計

當日最高
0.15
當日最低
0.14
52週最高
0.3
52週最低
0.12
成交量
65,415
平均成交量
78,520
市值
41.73M
市盈率
-
股息收益率
-
股息
-

收益

29Jul預期
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q2 2023
Q4 2023
Q2 2024
-0.03
-0.02
-0.01
0
預期每股收益
N/A
實際每股收益
N/A

人們還關注

此列表基於在 Stock Events 上關注 UBI.AU 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

關於

Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices used in healthcare (point-of-care), wine, food, and agriculture industries in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of the anticoagulant therapy warfarin; and Sentia wine testing products, such as free SO2, malic acid, glucose, fructose, total acid, and titratable acidity. It also offers non-diagnostic laboratory services and performs coagulation testing services. The company has a license agreement with LifeScan Global Corporation to develop a test strip and a meter to be used for the detection and monitoring of diabetes in non-humans. Universal Biosensors, Inc. was incorporated in 2001 and is based in Rowville, Australia.
Show more...
首席執行官
Mr. John Stewart Sharman B Ec, BECON, C.A., CA, M.App.Fin
員工
80
國家
AU
ISIN
AU000000UBI2

上市公司